p53 Pro72Arg polymorphism and prostate cancer in men of African descent

Ricks-Santi, Luisel; Mason, Terry; Apprey, Victor; Ahaghotu, Chiledum; McLauchlin, A.; Josey, David; Bonney, George E.; Dunston, Georgia M.

doi:10.1002/pros.21209

Cited by 24 publications

(26 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies carried out in Japan (22), China (23) and Northern India (24) reported the same increased association of the Pro allele with prostate cancer risk as the study by Quiñones et al (21), however, the studies of men in Argentina (27) and Iran (28) did not. One study by Ricks-Santi et al (26) found a significant association of the Arg allele with the prevalence of prostate cancer in populations of men of African descent.…”

Section: P21 C98a P21 C70t ------------------------------------------mentioning

confidence: 99%

“…The two variants were considered wild-type, resulting in a non-conservative change (6,15). In certain studies the Pro allele was associated with increased prostate cancer risk (21)(22)(23)(24)(25), while in others the Arg allele was associated with prostate cancer predisposition (26). Other studies, mainly larger studies and meta-analyses, did not detect any association of the p53 codon 72 polymorphism with prostate cancer risk (27)(28)(29)(30).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of p53 and p21 polymorphisms with prostate cancer

Sivoňová¹,

Vilčková²,

Kliment³

et al. 2015

Biomedical Reports

View full text Add to dashboard Cite

Abstract. Cell cycle deregulation is common in human cancer. Alterations of the tumor-suppressor gene p53 and its downstream effector p21 have been indicated in the development of numerous human malignancies. Therefore, we hypothesize that the p53 codon 72 polymorphism, either on its own or in combination with p21 (C98A and C70T) polymorphisms, modifies the risk of prostate cancer within the Slovak population, and no previous studies have investigated these gene-gene interactions in the pathogenesis of prostate cancer in the Slovak population. Polymerase chain reaction-restriction fragment length polymorphism was used to determine the p53 and p21 genotypes in subjects comprising 300 prostate cancer patients and 446 healthy individuals. These 3 polymorphisms individually did not correlate with the prostate cancer risk. Conversely, the interaction between the p53 and p21 polymorphisms significantly decreased the risk of prostate cancer, with the odds ratio (OR) being 0.49 [95% confidence interval (CI), 0.27-0.86; P<0.05] for subjects carrying the p53 codon 72 arginine (Arg)/proline (Pro)+Pro/Pro and p21 C98A CA genotypes compared to the combined reference genotypes p53 codon 72 Arg/Arg and p21 C98A CC. Neither the p53 genotypes nor the p21 genotypes showed statistically significant differences in Gleason score or serum prostate-specific antigen levels (P>0.05). A decreased risk of prostate cancer association with the p21 C98A CA genotype (OR=0.58; 95% CI, 0.36-0.93; P<0.05) in non-smokers compared to the non-smokers with the p21 C98A CC genotype was observed. Smokers carrying the p53 codon 72 Pro/Pro genotype were not at any significant risk of prostate cancer (OR=2.97; 95% CI, 0.51-17.15) compared to the non-smokers with the Arg/Arg genotype. Taken together, to the best of our knowledge this is the first study to show that a combination of the variant genotypes of p53 codon 72 and p21 C98A may modify the prostate cancer risk within the Slovak population.

show abstract

Section: P21 C98a P21 C70t ------------------------------------------mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Association of p53 and p21 polymorphisms with prostate cancer

Sivoňová¹,

Vilčková²,

Kliment³

et al. 2015

Biomedical Reports

View full text Add to dashboard Cite

show abstract

“…According to the inclusion criteria, seven studies (Henner et al, 2001;Suzuki et al, 2003;Huang et al, 2004;Wu et al, 2004;Leiros et al, 2005;Quinones et al, 2006;Ricks-Santi et al, 2010) were included in this meta-analysis and 68 studies were excluded. The flow chart of the study selection is summarized in Figure 1.…”

Section: Studies Included In the Meta-analysismentioning

confidence: 99%

Meta-analysis demonstrates no association between p53 codon 72 polymorphism and prostate cancer risk

Li¹,

Liu²,

Wu³

et al. 2011

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We examined whether p53 codon 72 polymorphism confers prostate cancer risk by conducting a meta-analysis. Two investigators independently searched the Pubmed, Embase and CBM databases. This meta-analysis was made of seven case-control studies, that included 892 prostate cancer cases and 1020 healthy controls. Meta-analysis results based on all the studies showed no significant association between p53 codon 72 polymorphism and prostate cancer risk in the comparisons of Pro allele vs Arg allele; Pro/Pro + Pro/Arg vs Arg/Arg; Pro/Pro vs Pro/Arg + Arg/Arg; Pro/Pro vs Arg/Arg, and Pro/ Arg vs Arg/Arg [odds ratio (OR) = 1.09, 95% confidence interval (CI) = 0.87-1.36, P = 0.47; OR = 1.22, 95%CI = 0.86-1.73, P = 0.27; OR = 1.03, 95%CI = 0.62-1.72, P = 0.91; OR = 1.22, 95%CI = 0.66-2.26, P = 0.52; OR = 1.25, 95%CI = 0.84-1.87, P = 0.27, respectively]. In 2925 ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 10 (4): 2924-2933 (2011) p53 codon 72 polymorphism and prostate cancer risk the subgroup analysis by ethnicity, no association was found between p53 codon 72 polymorphism and prostate cancer risk both in Caucasian and Asian populations. We found no association between p53 codon 72 polymorphism and prostate cancer risk.

show abstract

“…The Arg allele was differentiated from the Pro allele at codon 72 of TP53 by restriction fragment length polymorphism of PCR-generated amplicons using primers and the restriction enzyme BstU1 as published elsewhere. 10 Data were analyzed with Statview 5.0 (SAS Institute Inc., Cary, NC). Allele frequencies and genotypes were compared by the χ 2 test, and continuous variables by the Mann Whitney U test or Student's t test as applicable.…”

mentioning

confidence: 99%

No Association of the p53 Codon 72 Polymorphism with Malaria in Ghanaian Primiparae and Rwandan Children

Gai¹,

Meese²,

Bedu-Addo³

et al. 2014

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. The p53 protein is a key cell-signaling mediator integrating host responses to various types of stress. A common polymorphism of the encoding TP53 gene (codon 72, Pro Arg, rs1042522) is associated with susceptibility to virus-related and other cancers. The p53 has also been shown to be central for successful Plasmodium liver stage infection. We examined whether the polymorphism is associated with P. falciparum infection in Ghanaian primiparae and Rwandan children. The allele frequency of TP53 codon 72 Arg was 0.30 among 314 Ghanaian primiparae and 0.31 among 545 Rwandan children, respectively, and it was not associated with infection prevalence or parasite density. This does not exclude p53 to be of pathophysiological relevance in malaria but argues against a major respective role of the TP53 codon 72 polymorphism.In view of the ongoing burden of malaria, improved knowledge of pathophysiological mechanisms may provide novel targets for prevention and treatment.1 Recently, the p53 tumor suppressor protein, a central host cell-signaling factor, has been shown to be critical for successful Plasmodium liver stage infection.2 As a transcription factor, p53 responds to various stimuli to induce apoptosis or cell cycle arrest, or to integrate a variety of other host responses.3,4 Plasmodium liver stage parasites suppress p53 thereby promoting survival of the infected hepatocyte. Conversely, increased levels of p53 counterbalance this suppression and reduce liver stage parasite burden. 2The TP53 gene, encoding p53, shows a common single nucleotide polymorphism at codon 72 (proline to arginine, Pro Arg, rs1042522), conferring various functional consequences including the Arg allele being more effective at inducing apoptosis. 5 This allele has been associated with altered susceptibility to several virus-related and other cancers. 4,6 Notably, indirect evidence for a malaria-protective role of the TP53 codon 72 Arg allele is derived from a small study in Sardinia. 7 We, therefore, examined the distribution of the TP53 codon 72 alleles in two African populations with or without P. falciparum infection, i.e., placental P. falciparum infection in Ghanaian primiparae, and largely asymptomatic P. falciparum infection among Rwandan children.Socio-demographic, clinical, and parasitological characteristics of the two cross-sectional studies and the study groups have been reported elsewhere. 8,9 In brief, 314 primiparous pregnant women were recruited in southern Ghana of whom two-thirds (by polymerase chain reaction [PCR]) had largely asymptomatic placental P. falciparum infection (i.e., only 6.3% of these were febrile), which nevertheless was associated with maternal anemia, low birth weight, and preterm delivery. 8 The second group involved 545 children 5 years of age randomly selected from 24 rural villages in southern highland Rwanda of whom 16.1% were P. falciparum infected (by PCR; 2.9% categorized as symptomatic malaria defined as a positive blood film plus fever, or a history of fever within the preceding 48 hours...

show abstract

p53 Pro72Arg polymorphism and prostate cancer in men of African descent

Cited by 24 publications

References 55 publications

Association of p53 and p21 polymorphisms with prostate cancer

Association of p53 and p21 polymorphisms with prostate cancer

Meta-analysis demonstrates no association between p53 codon 72 polymorphism and prostate cancer risk

No Association of the p53 Codon 72 Polymorphism with Malaria in Ghanaian Primiparae and Rwandan Children

Contact Info

Product

Resources

About